814 Shares in Intuitive Surgical, Inc. (NASDAQ:ISRG) Bought by Legacy Capital Wealth Partners LLC

Legacy Capital Wealth Partners LLC purchased a new stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) in the 4th quarter, Holdings Channel.com reports. The institutional investor purchased 814 shares of the medical equipment provider’s stock, valued at approximately $275,000.

A number of other institutional investors also recently modified their holdings of the company. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA boosted its position in Intuitive Surgical by 0.3% during the fourth quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 8,899 shares of the medical equipment provider’s stock valued at $3,002,000 after acquiring an additional 27 shares during the last quarter. Liberty Capital Management Inc. boosted its stake in Intuitive Surgical by 3.8% during the 4th quarter. Liberty Capital Management Inc. now owns 815 shares of the medical equipment provider’s stock valued at $275,000 after purchasing an additional 30 shares during the last quarter. Miracle Mile Advisors LLC raised its position in Intuitive Surgical by 2.3% in the 4th quarter. Miracle Mile Advisors LLC now owns 1,438 shares of the medical equipment provider’s stock valued at $485,000 after buying an additional 32 shares during the last quarter. Ausdal Financial Partners Inc. grew its stake in shares of Intuitive Surgical by 1.5% in the 4th quarter. Ausdal Financial Partners Inc. now owns 2,192 shares of the medical equipment provider’s stock worth $739,000 after acquiring an additional 33 shares in the last quarter. Finally, Venturi Wealth Management LLC boosted its holdings in Intuitive Surgical by 10.7% in the 4th quarter. Venturi Wealth Management LLC now owns 341 shares of the medical equipment provider’s stock worth $115,000 after buying an additional 33 shares during the period. 83.64% of the stock is currently owned by institutional investors.

Intuitive Surgical Stock Performance

Shares of Intuitive Surgical stock opened at $374.14 on Tuesday. The company’s 50 day moving average price is $386.10 and its 200-day moving average price is $347.50. The stock has a market capitalization of $132.71 billion, a price-to-earnings ratio of 67.53, a P/E/G ratio of 4.85 and a beta of 1.36. Intuitive Surgical, Inc. has a 52-week low of $254.85 and a 52-week high of $403.76.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings data on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share for the quarter, topping analysts’ consensus estimates of $1.40 by $0.10. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The business had revenue of $1.89 billion for the quarter, compared to analysts’ expectations of $1.87 billion. During the same quarter in the prior year, the company earned $1.00 earnings per share. The business’s revenue was up 11.5% compared to the same quarter last year. As a group, equities research analysts forecast that Intuitive Surgical, Inc. will post 4.8 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Myriam Curet sold 5,318 shares of the company’s stock in a transaction on Tuesday, April 23rd. The stock was sold at an average price of $370.66, for a total transaction of $1,971,169.88. Following the transaction, the executive vice president now directly owns 298 shares of the company’s stock, valued at $110,456.68. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, Director Alan J. Levy sold 2,000 shares of the company’s stock in a transaction on Tuesday, April 23rd. The stock was sold at an average price of $370.70, for a total value of $741,400.00. Following the completion of the sale, the director now directly owns 25,319 shares in the company, valued at approximately $9,385,753.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Myriam Curet sold 5,318 shares of the firm’s stock in a transaction on Tuesday, April 23rd. The stock was sold at an average price of $370.66, for a total value of $1,971,169.88. Following the completion of the transaction, the executive vice president now directly owns 298 shares in the company, valued at $110,456.68. The disclosure for this sale can be found here. Over the last three months, insiders have sold 225,093 shares of company stock valued at $87,153,299. 0.80% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on ISRG. Stifel Nicolaus lifted their target price on Intuitive Surgical from $420.00 to $430.00 and gave the company a “buy” rating in a report on Monday, April 8th. StockNews.com cut shares of Intuitive Surgical from a “buy” rating to a “hold” rating in a research note on Thursday, February 29th. Jefferies Financial Group raised their price target on Intuitive Surgical from $365.00 to $375.00 and gave the company a “hold” rating in a report on Friday, April 19th. Raymond James upped their price objective on shares of Intuitive Surgical from $372.00 to $435.00 and gave the stock an “outperform” rating in a research report on Thursday, January 25th. Finally, BTIG Research raised their target price on shares of Intuitive Surgical from $412.00 to $421.00 and gave the company a “buy” rating in a research note on Friday, April 19th. Five research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $396.17.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.